Senator Hawley Introduces Legislation to Secure U.S. Medical Product Supply Chain in Light of Coronavirus Outbreak

Thursday, February 27, 2020

U.S. Senator Josh Hawley (R-Mo.) is introducing legislation to help secure the United States medical product supply chain. The Medical Supply Chain Security Act comes after reports of potential American drug shortages due to the Coronavirus outbreak in China.

“The coronavirus outbreak in China has highlighted severe and longstanding weaknesses in our medical supply chain. This is more than unfortunate; it’s a danger to public health. Our health officials need to know the extent of our reliance on Chinese production so they can take all necessary action to protect Americans. This legislation will give us the information we need to better secure our supply chain and ensure that Americans have uninterrupted access to life-saving drugs and medical devices.”

Senator Hawley

Earlier this week, Senator Hawley sent a letter to the Food and Drug Administration (FDA) demanding answers for what is being done to mitigate potential drug and medical device shortages here in the United States. Since the outbreak began, he has also called for the United States to consider restricting all commercial travel to and from China and requested federal agencies outline their plans on when and how to implement travel restrictions.

More information on the bill is available here or below.


The spread of the novel coronavirus in China has highlighted severe, longstanding, and unresolved vulnerabilities in the U.S. medical product supply chain. Slowing production at Chinese factories is impacting the supply of key components for pharmaceutical drugs and medical devices produced in the United States, threatening shortages of essential medical products. On February 23rd, Axios reported that the recent outbreak of novel coronavirus has threatened the domestic supply of some 150 pharmaceutical drugs, including antibiotics, generics, and branded drugs. Some of these drugs do not have alternatives in the market. This follows reports of widespread shortages of surgical masks and other personal protective equipment.

Currently, the ability of our public health officials to accurately measure and assess the vulnerability of our medical supply chain is limited. In its Congressional Budget Justification for fiscal year 2021, the FDA asked Congress for more statutory authority to require that manufacturers of medical devices notify the FDA when they become aware of circumstances that may lead to the shortage of an essential medical device. Such information would allow the FDA to ensure that they can take appropriate steps to mitigate potential shortages of life-saving and life-sustaining medical products.

This bill will give the FDA this authority and more. Our public health officials must be privy to the details of the manufacturing capacity of producers of essential drugs and medical devices so that they and Congress can take the necessary action to protect access to vital medical products in the United States. Stronger reporting requirements will help reveal the degree to which our medical product industry is reliant on Chinese production and uncover exactly how vulnerable our medical supply chain really is.

The Medical Supply Chain Security Act will:

  • Require that manufacturers report imminent or forecasted shortages of life-saving or life-sustaining medical devices to the FDA just as they currently do for pharmaceutical drugs. This new information on devices would be added to the FDA’s annual report to Congress on drug shortages.
  • Allow the FDA to expedite the review of essential medical devices that require pre-market approval in the event of an expected shortage reported by a manufacturer.
  • Give new authority to the FDA to request information from manufacturers of essential drugs or devices regarding all aspects of their manufacturing capacity, including sourcing of component parts, sourcing of active pharmaceutical ingredients, use of any scarce raw materials, and any other details the FDA deems relevant to assess the security of the U.S. medical product supply chain.